Figures computed from official regulatory filings — .
Analysttarget 20 USD (+2074%) · consensus 5/5 · 1 buy · 0 hold · 0 sell
Ownershipinsiders 0.53% · institutions 5.66% · short 1.3% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Creative Medical Technology Holdings, Inc., a commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness. It develops AlloStem (CELZ-201-DDT), a allogenic human perinatal tissue derived cell program, ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, which is phase 2, for the treatment of type 1 diabetes; AlloStemSpine (CELZ 201 ADAPT), which is phase 2, for the treatment of chronic lower back pain; Alova, a platform to treat infertility as a result of premature ovarian failure; StemSpine, a regenerative stem cell procedure to treat degenerative disc disease; OvaStem, a stem cell therapy for premature ovarian failure; CaverStem for erectile dysfunction treatment; and FemCelz for female sexual function treatment. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
23 buys24 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Warbington Timothytrack record | Award | n/a (No price was disclosed in the filing) | SEC |
| Finger Michael H. | Sell | $3.8K | SEC |
| Finger Michael H. | Sell | $4.3K | SEC |
| Warbington Timothytrack record | Buy | $1.3K | conv 46 | SEC |
| Warbington Timothytrack record | Buy | $896 | conv 46 | SEC |
| Warbington Timothytrack record | Buy | $1.3K | conv 46 | SEC |
| Warbington Timothytrack record | Buy | $872 | conv 40 | SEC |
| Warbington Timothytrack record | Buy | $2K | conv 35 | SEC |
| Warbington Timothytrack record | Buy | $3.8K | conv 35 | SEC |
| Warbington Timothytrack record | Buy | $4K | conv 38 | SEC |
| Warbington Timothytrack record | Buy | $76 | conv 31 | SEC |
| Finger Michael H. | Buy | $1K | conv 43 | SEC |
| Warbington Timothytrack record | Buy | $10K | conv 44 | SEC |
| Warbington Timothytrack record | Buy | $2.9K | conv 41 | SEC |
| Warbington Timothytrack record | Buy | $12.2K | conv 54 | SEC |
| Warbington Timothytrack record | Buy | $3.1K | conv 42 | SEC |
| Warbington Timothytrack record | Buy | $6.5K | conv 39 | SEC |
| Warbington Timothytrack record | Buy | $315 | conv 36 | SEC |
| Finger Michael H. | Buy | $7K | conv 69 | SEC |
| Warbington Timothytrack record | Buy | $7.4K | conv 94First in 12mo | SEC |
| Warbington Timothytrack record | Buy | $13.7K | conv 94First in 12mo | SEC |
| Warbington Timothytrack record | Buy | $1.8K | conv 94First in 12mo | SEC |
| Finger Michael H. | Buy | $9.8K | conv 77First in 12mo | SEC |
| Warbington Timothytrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Dickerson Donald | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |